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Purpose: The stage of disease is one of the strongest prognostic factors in epithelial ovarian 
cancer. The International Federation of Gynecology and Obstetrics (FIGO) classification was 
revised in 2013; stage IC was subdivided into IC1 (intraoperative surgical spill), IC2 (capsule 
rupture before surgery or tumor on surface), and IC3 (positive peritoneal washing or ascites). 
Our aim was to compare the outcome of patients in the new FIGO stage I subgroups, as this 
might influence adjuvant therapy decisions.
Patients and methods: Patient databases of three gynecological oncology centers were ret-
rospectively analyzed. Patients with FIGO stage I ovarian cancers were restaged according to 
the revised classification, based on operative and pathological reports, and determined patient 
outcomes.
Results: We analyzed 128 patients with ovarian cancers. In FIGO IA, we found 11.3% recur-
rences and 4.2% deaths. In FIGO IC, 21.8% of the patients recurred and 7.3% died. There was 
a trend toward a shorter time to recurrence when comparing IA to IC (P=0.076). Within all new 
subgroups of FIGO IC, there was no difference in time to recurrence (P=0.59). There was also no 
significant difference in survival when FIGO IA was compared to FIGO IC in comparison with 
the new individual classifications (IA to IC, IA to IC1, 2, or 3; P=0.60, P=0.15, P=0.61, P=0.66, 
respectively) or within the different subgroups (P=0.56). Platinum-based chemotherapy was 
given to the majority (82.6%, n=38/46) of the FIGO IC patients compared to 30.9% in FIGO IA 
(n=17/55). There was no significant difference within the new subgroups of FIGO IC (P=0.88).
Conclusion: In our retrospective analysis, the new FIGO staging of IC ovarian cancers did 
not predict prognosis, but the use of adjuvant chemotherapy in 82.6% of the stage IC patients 
may have biased the outcome.
Keywords: ovarian neoplasm, cancer staging, survival, recurrence
Introduction
Epithelial ovarian cancer is the fifth most common cancer among women. In Europe, 
about 42,000 women are diagnosed with ovarian cancer and 29,200 women die from 
this disease each year.1 About one quarter of patients present with early ovarian cancer 
(International Federation of Gynecology and Obstetrics [FIGO] stages I and II), where 
the overall 5-year survival is reported to be between 80% and 90%.2
For ovarian cancer, FIGO staging system is commonly used, and, especially in early 
ovarian cancer, surgical and pathological staging is crucial. The purpose of a unified 
staging system is as follows: first, to develop an accurate and universal terminology to 
describe the extent of disease; second, to allocate patients to prognostic subgroups; and 
third, to compare treatment efficacy and survival outcomes between centers as part of 
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clinical trials and research.3 The stage should reflect the extent 
of the metastatic tumor burden and, most importantly, prognosis.
Along with histological type, grade, and residual disease, 
stage is a powerful prognostic factor. Up to one-third of 
patients with apparent early ovarian cancer are upstaged when 
proper surgical staging is performed, and surgical staging 
is an independent prognostic factor for survival.4 Complete 
surgical staging should include peritoneal washings, hys-
terectomy, bilateral salpingo-oophorectomy, omentectomy, 
multiple peritoneal biopsies, and pelvic and para-aortic 
lymphadenectomy. Bilateral ovarian lesions (P<0.001), posi-
tive cytology (P=0.012), presence of ascites (P=0.002), high-
grade histology (P<0.001), and serous histology (P=0.001) 
are risk factors for lymph node involvement, which should 
be considered in counseling patients for restaging after 
unexpected findings of malignancy and incomplete surgery.5
The 1988 FIGO classification for cancer of the ovary 
was revised in 2013 after 24 years of use (Table 1).6 The 
objective of this study was to evaluate the clinical impact of 
the new classification system on early-stage ovarian cancer, 
particularly the new subgroups of stage IC.
Patients and methods
We retrospectively reviewed all cases of FIGO stage I epi-
thelial ovarian and fallopian tube cancers from the databases 
of three major gynecological oncology centers from two 
countries (Switzerland and Australia): The Women’s Hospi-
tal, University Hospital of Basel, Switzerland, The Women’s 
Hospital, University Hospital of Zurich, Switzerland, and The 
Royal Hospital for Women in Sydney, Australia, in the time 
frame between 1992 and 2015. Our final cohort consisted 
of 128 cases of FIGO I ovarian cancer (n=124) and FIGO I 
fallopian tubal cancer (n=4).
Demographical, surgical, histological, treatment, and 
outcome data of these patients were analyzed. We restaged 
the patients according to the new FIGO guidelines from a 
homogenous group of IC to IC1, IC2, and IC3. Restaging to 
IC1 was based on operative reports confirming intraopera-
tive rupture. Restaging to IC2 and IC3 was based on both 
operative and pathology reports confirming capsule rupture 
before surgery, tumor seeds on the surface of the ovary, or 
positive peritoneal washing cytology.
Complete surgical staging included peritoneal washings, 
hysterectomy, bilateral salpingo-oophorectomy, pelvic and 
para-aortic lymphadenectomy, infracolic omentectomy, and 
multiple peritoneal biopsies.
After surgery, the indication for adjuvant chemotherapy 
was discussed at an interdisciplinary tumor board for all 
cases. Adjuvant chemotherapy consisted of platinum-based 
chemotherapy. No chemotherapy was given for cases of grade 
1, FIGO stages IA and IB tumors. Patients were followed 
up every 3 months for the first 2 years, half-yearly for up 
to 5 years, and then annually until 10 years. Patients were 
monitored clinically, biochemically by tumor markers, and 
radiologically (baseline CT directly after surgery, further CT 
indicated by clinical and/or biochemical suspicion of relapse).
statistical methods
Relapse-free survival (RFS) and disease-specific survival 
(DSS) were displayed as Kaplan–Meier curves with corre-
sponding P-values of the log-rank test. Additionally, number 
at risk and number of events were reported for each group 
Table 1 Details of the FIGO classification for ovarian and fallopian tube(s) cancers: old 1988 vs new 2013 FIGO staging
Old – 1988 FIGO stage New – 2013 FIGO stage
Stage I IA Tumor limited to one ovary, capsule 
intact, no tumor on ovarian surface, and 
negative washings/ascites
IA Tumor limited to one ovary or fallopian tube, 
capsule intact, no tumor on surface, and 
negative washings/ascites
IB Tumor involves both ovaries, capsule 
intact, no tumor on ovarian surface, and 
negative washings/ascites
IB Tumor limited to both ovaries or fallopian 
tubes, capsule intact, no tumor on surface, 
and negative washings/ascites
IC Tumor limited to ovaries with any of 
the following: capsule rupture, tumor on 
ovarian surface, or positive washing/ascites
IC Tumor limited to one or both ovaries or 
fallopian tube
iC1 •	 With surgical spill
iC2 •	 With capsule rupture before surgery or 
tumor on ovarian or fallopian tube surface
iC3 •	 With malignant cells in the ascites or 
peritoneal washings
Abbreviation: FigO, international Federation of gynecology and Obstetrics.
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separately. Comparisons of RFS and DSS within individual 
subgroups were done using the log-rank test.
In order to compare chemotherapy-adjusted RFS between 
study groups, Cox regression was performed. Results are 
reported as HR with corresponding 95% CI and P-values. 
DSS comparison was not done because of low number of 
events.
In the case of ordinal or metric variables, median and 
interquartile range with corresponding Wilcoxon tests were 
calculated. In the case of categorical variables, counts and 
percentages were reported, and Fisher’s exact test was per-
formed. A P-value of <0.05 was considered as significant. 
All evaluations were performed using the statistical software 
R, version 3.2.1.
The study was approved by the respective medical ethics 
committees: the Ethikkommission Nordwest- und Zentralsch-
weiz (EKNZ BASEC 2016-01011) and the Hunter New 
England Human Research Ethics Committee (HNEHREC 
16/04/20/5.06). Patient consent to review their medical 
records was not required by the ethics committees for the 
time frame of this study (patient database from 1992 up to 
2015). The study was retrospective and constituted no harm 
for patients. Patient data confidentiality has been protected, 
and the medical data were used anonymously. As required 
by the ethics committees, this study has been conducted in 
compliance with the protocol, the current version of the 
Declaration of Helsinki, the ICH-GCP or ISO EN 14155 (as 
far as applicable) as well as all national legal and regulatory 
requirements.
Results
Our databases collectively consisted of data of 2,957 patients 
with gynecological tumors diagnosed in the time frame 
between 1992 and 2015. Of these, we identified 131 perito-
neal cancers, 1,020 ovarian cancers, and 48 tubal cancers. 
We excluded all cases other than epithelial ovarian and tubal 
cancers, FIGO stage I. Patients with synchronous tumors 
of the ovary/tube and endometrial cancer (n=12) were also 
excluded. Of the epithelial ovarian and tubal cancer cases, 
206 were determined to be of FIGO stage I. After excluding 
borderline ovarian tumors (n=78), we were left with a final 
cohort of n=128 consisting of FIGO I ovarian cancer (n=124) 
and FIGO I fallopian tubal cancer (n=4). The histology of 
these cases was as follows: serous 28.1% (n=37), endome-
trioid 25.8% (n=33), mucinous 25% (n=32), clear cell 12.5% 
(n=16), mixed (including carcinosarcoma) 6.9% (n=9), and 
transitional cell 1.6% (n=2). Tumor grade (n=103) was as 
follows: grade 1 (n=37) 35.9%, grade 2 (n=26) 25.2%, and 
grade 3 (n=40) 38.8%. FIGO stages at diagnosis consisted of 
IA (n=71) 55.5%, IB (n=2) 1.5%, and IC (n=55) 43%. Upon 
restaging, the FIGO IC group consisted of FIGO IC1 (n=14) 
10.9%, IC2 (n=11) 8.6%, and IC3 (n=30) 23.5%. The mean 
age was 56.6 years (SD=15.1). Mean length of follow-up was 
59.4 months (range 0–258 months) (Table 2).
The outcome has been measured on the entire cohort 
(n=128). We performed a survival analysis and defined RFS 
as the time from the initial treatment (surgery) to relapse or 
the last follow-up visit. We observed a total of 20 recurrences, 
reported by stage: IA n=8/68, IB n=0/1, IC1 n=2/14, IC2 
n=3/11, and IC3 n=7/27. The repartition of the recurrences 
by histological type was as follows: serous 30.0% (n=6), 
endometrioid 30.0% (n=6), mucinous 10.0% (n=2), clear cell 
10.0% (n=2), mixed (including carcinosarcoma) 20% (n=4), 
and transitional cell 10.0% (n=2). Patients with recurrence 
and their characteristics are listed in Table 3. DSS was defined 
as the time from the initial treatment to death due to initial 
diagnosis. We reported six deaths in our cohort, namely in 
the group of FIGO stages IA n=3/68, IB n=0/1, IC1 n=1/14, 
IC2 n=0/11, and IC3 n=2/27. Kaplan–Meier curves for the 
RFS and DSS are shown in Figures 1–4.
To define the staging quality of our cohort, we analyzed the 
surgical reports of each patient. In 12 patients we had insuf-
ficient data to evaluate the extent of staging. Therefore, these 
patients were excluded from this part of the analysis. Complete 
surgical staging, including systematic pelvic and paraaortic 
lymphadenectomy, was performed in 72 patients (n=116, 
62.1%). Systematic intraperitoneal staging, however, without 
lymphadenectomy was performed in 34 patients (29.3%). 
A further 10 patients (8.6%) were incompletely staged; the 
reason in most cases reflected the patient’s choice, and in one 
case it was because of fertility preservation. Patients were not 
excluded from the other analysis based on their staging status.
ia vs iC
Of the FIGO IA cases, there were eight recurrences (11.3%) 
and three deaths (4.2%). The 5-year RFS was 87%, and the 
5-year DSS was 98%. For all subgroups of IC, there were 
12 recurrences (21.8%) and four deaths (7.3%), the 5-year 
RFS was 67%, and the 5-year DSS was 98%. There was no 
significant difference in RFS or DSS (P=0.076 and 0.60, 
respectively) between FIGO stages IA and IC as measured 
by the log-rank test.
iC1 vs iC2 vs iC3
When comparing the new subgroups of FIGO IC, the 5-year 
RFS was 62% (IC1), 78% (IC2), and 59% (IC3) (P=0.59). 
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Table 2 Patient characteristics
Baseline 
characteristics
All IA IB IC1 IC2 IC3 P-value N
n=128 n=71 n=2 n=14 n=11 n=30
Primary site 0.071 128
•	 Ovary 124 (96.9%) 71(100%) 2 (100%) 13 (92.9%) 10 (90.9%) 28 (93.3%)
•	 Fallopian tube 4 (3.12%) 0 0 1 (7.14%) 1 (9.09%) 2 (6.67%)
Histology 0.300 128
•	 serous 36 (28.1%) 14 (19.7%) 1 (50.0%) 3 (21.4%) 4 (36.4%) 14 (46.7%)
•	 Clear cell 16 (12.5%) 13 (18.3%) 0 1 (7.14%) 0 2 (6.67%)
•	 endometrioid 33 (25.8%) 18 (25.4%) 1 (50.0%) 6 (42.9%) 3 (27.3%) 5 (16.7%)
•	 Mucinous 32 (25.0%) 22 (31.0%) 0 4 (28.6%) 2 (18.2%) 4 (13.3%)
•	 Transitional 2 (1.56%) 1 (1.41%) 0 0 0 1 (3.33%)
•	 MMMT, mixed 9 (6.98%) 3 (4.17%) 0 0 2 (18.2%) 4 (13.33%)
Gradea 0.011 103
•	 g1 37 (35.9%) 27 (49.1%) 0 5 (45.5%) 2 (22.2%) 3 (11.1%)
•	 g2 26 (25.2%) 14 (25.5%) 0 2 (18.2%) 3 (33.3%) 7 (25.9%)
•	 g3 40 (38.8%) 14 (25.5%) 1 (100%) 4 (36.4%) 4 (44.4%) 17 (63.0%)
•	 Missing 25
Staginga 0.426 116
•	 Complete 72 (62.1%) 39 (60.9% 0 8 (57.1%) 6 (66.7%) 19 (70.4%)
•	 incomplete 44 (37.9%) 25 (39.1%) 2 (100%) 6 (42.9%) 3 (33.3%) 8 (29.6%)
•	 Missing 12
Chemotherapya >0.001 102
•	 no 46 (45.1%) 38 (69.1%) 0 2 (18.2%) 2 (22.2%) 4 (15.4%)
•	 Yes 56 (54.9%) 17 (30.9%) 1 (100%) 9 (81.8%) 7 (77.8%) 22 (84.6%)
•	 Missing 26
Follow-up months, 37.0  
[12.5; 92.5]
35.0  
[12.0; 111]
19.0  
[19.0; 19.0]
35.5  
[12.5; 66.5]
60.0  
[36.0; 92.5]
27.0  
[13.0; 68.2]
0.803 123
median (iQR)
Missing 5
Age, years 56.0  
[45.0; 68.0]
60.0  
[47.5; 67.5]
67.0  
[57.5; 76.5]
46.5  
[41.5; 56.0]
59.0  
[42.0; 69.5]
55.0  
[45.5; 68.8]
0.206 128
Notes: aPercentages calculated excluding missing values from denominator. n, number available for each variable; Missing, information on patient was missing; Chemotherapy, 
adjuvant platinum-based chemotherapy.
Abbreviations: iQR, interquartile range; MMMT, malignant mixed Mullerian tumor or carcinosarcoma; n, number.
The 5-year DSS was 100% (IC1), 100% (IC2), and 96% 
(IC3) (P=0.56).
ia vs iC1, iC2, and iC3, respectively
There was no significant difference in RFS or DSS when 
comparing FIGO IA to IC1, IC2, or IC3 individually (RFS: 
P=0.47, P=0.23; P=0.07, respectively, and DSS: P=0.14; 
P=0.61, P=0.66, respectively). The FIGO group IB could 
not be compared to the other groups because the study had 
only one patient with that stage.
sub-analysis
We performed a sub-analysis by grade and histological 
subtype; however, neither of these showed any significant 
differences in RFS or DSS with the log-rank test. For high 
grade (G3) tumors (n=40), the stages were as follows: FIGO 
IA n=14, IB n=1, IC1 n=4, IC2 n=4, and IC3 n=17. The 
survival analysis showed no significant difference between 
all groups, RFS P=0.68 and DSS P=0.9. Within the serous 
histology (n=37; FIGO IA n=14, IB n=1, IC1 n=3, IC2 n=4, 
and IC3 n=14), there was no significant difference for the 
RFS (P=0.62) as well as for the DSS (P=0.63)
Chemotherapy
In the FIGO stage IA group, platinum-based chemotherapy 
was administered in 30.9% (n=17) of the patients, while in 
FIGO IC 82.6% (n=38) received this treatment. Within the 
FIGO IC group, there was no difference in chemotherapy 
administration rates between the new sub-classifications; 
chemotherapy for FIGO IC1, IC2, and IC3 was administered 
in 81.8% (n=9), 77.8% (n=7), and 84.6% (n=22) of cases, 
respectively. As expected, the adjuvant therapeutic proce-
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dure differs significantly between the FIGO IA, IB, and IC 
(P<0.001), but not within the new FIGO IC subclassification 
(P=0.88).
We also performed a multivariate regression analysis to 
compare chemotherapy-adjusted RFS between study groups. 
There was no significant HR. The comparison was not per-
formed for DSS because of very small number of events 
(deaths n=6). The results are reported in Table 4.
No additional multivariate Cox model (adjusting for 
other study parameters) was done as the inclusion of several 
covariates in a study with relatively small event rates can lead 
to spurious results.7
Table 3 Patients with recurrence and FigO i stage disease
Baseline characteristics Recurrence
n=20
Primary site
•	 Ovary 19 (95%)
•	 Fallopian tube 1 (5%)
Histology
•	 serous 6 (30.0%)
•	 Clear cell 2 (10.0%)
•	 endometrioid 6 (30.0%)
•	 Mucinous 2 (10.0%)
•	 Transitional 0
•	 MMMT, mixed 4 (20.0%)
FIGO stage
•	 ia 8 (40.0%)
•	 iB 0
•	 iC1 2 (10.0%)
•	 iC2 3 (15.0%)
•	 iC3 7 (35.0%)
Gradea
•	 g1 4 (25.0%)
•	 g2 5 (31.2%)
•	 g3 7 (43.8%)
•	 Missing 4
Staginga
•	 Complete 10 (66.7%)
•	 incomplete 5 (33.3%)
•	 Missing 5
Chemotherapya
•	 no 3 (20.0%)
•	 Yes 12 (80.0%)
•	 Missing 5
Follow-up months, median (IQR) 46.0 [7.00; 174]
Age, years 61.0 [23.0; 85.0]
Notes: aPercentages calculated excluding missing values from denominator. Missing, 
information on patient was missing; Chemotherapy, adjuvant platinum-based 
chemotherapy.
Abbreviations: FigO, international Federation of gynecology and Obstetrics; iQR, 
interquartile range; MMMT, malignant mixed Mullerian tumor or carcinosarcoma; n, 
number.
Figure 1 Relapse-free survival using the old FIGO classification system for the 
cohort of 128 patients with ovarian and tubal cancers in FigO i stage.
Abbreviation: FigO, international Federation of gynecology and Obstetrics.
Figure 2 Relapse-free survival using the new FIGO classification system for the 
cohort of 128 patients with ovarian and tubal cancers in FigO i stage.
Abbreviation: FigO, international Federation of gynecology and Obstetrics.
Figure 3 Disease-specific survival using the old FIGO classification system for the 
cohort of 128 patients with ovarian and tubal cancers in FigO i stage.
Abbreviation: FigO, international Federation of gynecology and Obstetrics.
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In our analysis on 128 ovarian cancers, the revised 
FIGO system for stage I did not add prognostic informa-
tion. We could not confirm that surgical spill would have 
a similar outcome as a FIGO IA stage. FIGO IC showed 
more recurrences and deaths compared to FIGO IA (21.8% 
vs 11.3% recurrences, 7.3% vs 4.2% deaths). There was a 
trend toward a shorter time to recurrence when comparing 
IA to IC (P=0.076), however, without impact on survival. 
There was also no significant difference in survival when 
FIGO IA was compared to FIGO IC in comparison with 
the new individual classifications or within the different 
subgroups.
Nevertheless, the particularity of our cohort is a substan-
tially higher percentage of completely and correctly staged 
patients (62.1%) compared to other studies. A complete 
surgical staging procedure in early-stage ovarian and fallo-
pian tube cancers should include hysterectomy with bilateral 
salpingo-oophorectomy, pelvic and paraaortic lymph node 
dissection as well as omentectomy, peritoneal washings, 
peritoneal biopsies, and biopsies of any suspicious nodules.8 
Incomplete staging could lead to incorrect staging.
Clear prognostic differences between different subgroups 
of FIGO I should lead to adjuvant treatment recommenda-
tions, particularly with respect to adjuvant platinum-based 
chemotherapy. Only one study, facilitating a nationwide 
register, has shown that FIGO IA and IC1 (surgical spill 
intraoperatively) have a similar prognosis.9 Rosendahl et al 
published data on 4,036 ovarian cancer patients who were 
assigned to the new stages9 and illustrated similar survival 
characteristics in two groups: FIGO IA (n=464) with IC1 
(n=143) (5-year overall survival [OS], 87%), and FIGO IB 
(n=51) with IC2 (n=195) and with IC3 (n=140) (5-year OS, 
75%–80%). This suggests that surgical spillage has little or 
no significance, which is a relevant finding for gynecologi-
cal oncologists operating on such patients. One significant 
problem in this cohort, however, is the high percentage of 
incompletely staged patients (in stages IA–IIB lymphadenec-
tomy was only performed in 30%–43% and omentectomy 
in 81%–93% of cases).9 Patients with positive lymph nodes, 
occult peritoneal, or omental metastases would have been 
upstaged and could have modified the results found on the 
survival.
During the revision process of the new FIGO classifica-
tion, Suh et al analyzed 254 cases with FIGO stage I disease. 
The breakdown by subtype was as follows: IA n=128, IB 
n=7, and IC n=119 (IC1: 39; IC2: 27, and IC3: 53). The 
5-year OS rates of patients with stage IA were 93.5% and 
with substages IC1, IC2, and IC3 were 92.0%, 85.0%, and 
Figure 4 Disease-specific survival using the new FIGO classification system for the 
cohort of 128 patients with ovarian and tubal cancers in FigO i stage.
Abbreviation: FigO, international Federation of gynecology and Obstetrics.
Table 4 subgroups comparison reported as hR adjusted for 
chemotherapy, with lower and upper 95% confidence limits
Comparison HR LCL UCL P-value
ia vs iC1 1.83 0.19 18.02 0.604
ia vs iC2 0.98 0.17 5.65 0.981
ia vs iC3 0.56 0.14 2.18 0.404
iC1 vs iC2 0.53 0.05 5.96 0.611
iC1 vs iC3 0.31 0.04 2.52 0.273
iC2 vs iC3 0.57 0.12 2.8 0.492
Abbreviations: LCL, lower confidence limit; UCL, upper confidence limit.
Discussion
FigO staging
With the updated 2013 FIGO staging for ovarian, fallopian 
tube, and primary peritoneal cancers, the quantitative 
number of substages changed from 10 to 14.6 Staging 
underwent a major revision and became more demanding 
as the same number of patients are now distributed in a 
larger number of categories, thereby decreasing patient 
numbers per substage. The consequence of this is that it 
becomes more difficult to show a real difference between 
the different subgroups.
Our study focused on the impact of the stratification of 
FIGO IC, which has been divided into the following three 
further categories: IC1, surgical spill intraoperatively, IC2, 
capsular ruptured before surgery or tumor on ovarian or fal-
lopian tube surface, and IC3, malignant cells in the ascites or 
peritoneal washings. Intuitively, one would think that an iatro-
genic capsule rupture, following which the peritoneal cavity 
can be washed with water, should not have the same clinical 
impact as an ovarian cancer, which has already spontaneously 
spread, as demonstrated by positive peritoneal washings.
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71.0%, respectively (P=0.004). These data suggested that 
patients with surgical spillage had the best outcome which 
seems somehow difficult to anticipate.10
Paik et al investigated the influence of the revised FIGO 
staging system on 200 cases of FIGO stage I disease. The 
subgroups were as follows: IA n=96, IB n=6, and IC n=98 
(IC1: 9; IC2: 57; and IC3: 32).11 They were unable to show 
a significant difference between the groups and subgroups 
in the new classification using univariate analysis. In multi-
variate analysis, FIGO stage IC3 was shown to have a sig-
nificantly worse progression-free survival (PFS) (P=0.011), 
but not on OS. This may be due to a lack of statistical power 
because of low numbers.11
The survival outcome in our cohort was better com-
pared to the prior reports with a 5-year DSS in FIGO I of 
96%–100%. We reported both the 5-year RFS and 5-year 
DSS as FIGO IA 87% and 98% and FIGO IC 67% and 98%, 
respectively. Within the FIGO IC subgroup, the 5-year RFS 
was 62% (IC1), 78% (IC2), and 59% (IC3), and the 5-year 
DSS was100% (IC1), 100% (IC2), and 96% (IC3).
Role of classification systems
Recent findings in ovarian cancer research underline a new 
approach to this heterogeneous disease due to different 
groups of tumors with different characteristics, phenotypes, 
origins, and biology.12 However, the aim of a classification 
system for malignancy should be to assign patients to groups 
that allow meaningful stratification for prognosis. It should 
also offer easy communication with standard terminology 
among physicians, allowing comparison between centers 
and consistency for clinical trials. Finally, it should be easy 
to use and reproducible.3,6,13,14
The tumor biology is not integrated into the actual clas-
sification, although low and high grade, ovarian and fallopian 
tube cancers are different molecular entities and behave in 
different ways. We, therefore, performed a subgroup analysis 
for high and low grade and for serous and non-serous ovarian 
and tubal cancers. There was no survival difference between 
the groups. However, the cancer heterogeneity could be the 
reason why Paik et al have a significant result only after 
multivariate analysis excluding other prognostic cofounders,11 
and why the literature shows such divergent results.9,10,15 The 
new FIGO classification appears to be generally more dif-
ficult to apply in daily practice, and research analysis is more 
difficult due to a smaller number of cases in each subgroup. 
The retrospective character of the trials and their selection 
bias must also be taken into account.
incomplete staging
Incomplete staging is a major source of bias. The strength 
of this study is the low level of incompletely staged 
patients (37.9%). A systematic intraperitoneal staging 
with peritoneal washings, hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, and multiple biopsies was 
performed in 91.4% of the cases, including 62.1% of the 
completely staged patients with systematic pelvic and para-
aortic lymphadenectomy. Trimbos et al included 40 centers 
in nine European countries with a precise protocol as part 
of a randomized Phase III trial (ACTION Trial)16 to study 
the impact of adjuvant chemotherapy and surgical staging 
in early-stage ovarian carcinoma. However, even in this 
randomized trial in which comprehensive surgical staging 
was a requirement in the study protocol, the majority of 
patients (66%) were incompletely staged with one or more 
staging procedures omitted.17
The high level of fully staged patients in this study is 
explained by the fact that all operations were performed 
within gynecological cancer centers, with trained gyneco-
logical oncology surgeons available to perform the staging 
procedure. If the cancer diagnosis had been made unexpect-
edly and the staging was insufficient, a second operation to 
complete the staging was strongly recommended. In 29.3% 
of the cases, there was no staging lymphadenectomy, usu-
ally due to patient’s choice. Paik et al showed a significant 
prognostic impact on PFS for stage IC3 in the multivariate 
analysis only by adjusting age, cell type, grade, and surgical 
staging methods (complete staging vs incomplete staging), 
which underlines the impact of staging on survival.
To further illustrate the importance of complete surgical 
staging, it has recently been shown that in patients with stages 
I–IIA ovarian cancer who had ≥10 lymph nodes removed, 
there was no further benefit from chemotherapy. This was 
also true for a subgroup of patients with high-risk features 
(stages IC and IIA and/or tumor grade 3 and/or clear cell 
histology).18
Chemotherapy effect
Another important potential bias comes from chemotherapy. 
Two parallel prospective randomized trials have addressed 
the issue of adjuvant chemotherapy in patients with early-
stage ovarian cancer16,19 but only one, the ACTION study, 
required complete surgical staging. The Adjuvant Chemo-
therapy in Ovarian Neoplasm (ACTION) trial study is a 
prospective randomized Phase III trial that tests the efficacy 
of adjuvant chemotherapy in 448 patients from 40 centers 
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in nine European countries with early-stage ovarian cancer, 
with emphasis on the extent of surgical staging. Patients were 
randomized in two arms after surgery, namely 1) adjuvant 
platinum-based chemotherapy (n=224) or 2) observation 
only (n=224).16 After a median follow-up of 5.5 years, there 
was no significant difference in OS between the two arms, in 
contrast to the RFS which was significantly improved in the 
adjuvant chemotherapy arm (HR =0.63, 95% CI =0.43–0.92, 
P=0.10). One-third of patients were optimally staged, but 
two-third were not. The long-term analysis of the ACTION 
Trial20 after a median follow-up of 10.1 years demonstrated 
that OS after optimal surgical staging was improved, even 
among patients who received adjuvant chemotherapy (HR 
=1.89, 95% CI =0.99–3.60, P=0.05), however, the benefit 
from adjuvant chemotherapy in early-stage ovarian cancer 
was limited to patients with nonoptimal surgical staging. 
Patients (n=477) in the  International Collaborative Ovar-
ian Neoplasm trial 1 (ICON1) study were recruited in 84 
centers in five countries and were randomized in one group 
which received adjuvant chemotherapy immediately after 
surgery (n=241) or in another group without chemotherapy 
until clinically indicated (n=236).19 A complete surgical stag-
ing was not required, the staging procedure was not recorded, 
so that the proportion of optimally staged patient remains 
unknown. With a median follow-up of 4 years, ICON1 demon-
strated a significant improvement in RFS (HR =0.66, 95% CI 
=0.45–0.97) and OS (HR =0.66, 95% CI =0.45–0.97, P=0.03) 
when chemotherapy was given. With a median follow-up of 
10 years, the long-term data reported a 10% improvement 
in RFS and a 9% improvement in OS with the addition of 
chemotherapy.21 A high-risk group of patients, defined as 
stage IB/IC grade 2/3, any stage I grade 3, or with clear-cell 
histology might have a greater benefit, with an 18% improve-
ment in OS reported. These results were consistent with the 
ACTION Trial, in which patients not fully staged did benefit 
from adjuvant chemotherapy, but still did not do as well as 
properly staged patients without adjuvant chemotherapy.
The choice and the duration of chemotherapy for patients 
with stage I ovarian cancer remains controversial. In the 
ICON1 study, six cycles of platinum-based chemotherapy 
were recommended, and 87% of the patients received single-
agent carboplatin.16 The retrospective analysis of the ICON3 
trial for early-stage ovarian cancer showed a trend toward 
improved PFS in favor of the combination of carboplatin/
paclitaxel instead of carboplatin alone, but no difference in 
OS.22 The GOG 157 study compared 3 vs 6 cycles of carbo-
platin/paclitaxel and no difference was shown in RFS or OS 
between the regimens, although increased toxicity occurred 
with 6 cycles.23
In our study, we have accurate data on chemotherapy 
available for each individual case, based on an interdisciplin-
ary tumor board decision in accordance with the international 
guidelines. For patients with FIGO stage IC disease, 82.6% 
received platinum-based chemotherapy. The majority of 
patients who did not receive adjuvant chemotherapy declined 
it despite our recommendation.
Tumor rupture
Rosendahl et al suggested that possible explanations for the 
similar survival rates of substages IA and IC1 were that 1) 
surgical spill has no significance or 2) patients with stage IC1 
disease were treated with adjuvant chemotherapy.9 In a large 
international retrospective study on 1,545 patients, Vergote 
et al looked at the prognostic factors in stage I invasive 
epithelial ovarian cancer. In the multivariate analyses, the 
most powerful prognostic indicator of DSS was the degree 
of differentiation (poorly vs well differentiated), with a HR 
of 8.89 (4.96–15.9), followed by rupture of the tumor during 
surgery with a HR of 1.64 (1.07–2.51), FIGO stage 1973 
IB vs IA HR of 1.70 (1.01–2.85), and age (per year HR of 
1.02 [1.00–1.03]).24 As different adjuvant modalities (che-
motherapies vs observation) were permitted in this study, 
the impact on the outcome remains difficult to appreciate 
and represents a potential bias. Still rupture of the capsule 
should be avoided during surgery if possible,25 but the data 
are controversial. It remains unclear whether intraoperative 
capsule rupture worsens prognosis.2,6,12,26–28
A recently published meta-analysis reported that intra-
operative rupture might not decrease PFS compared to no 
rupture in patients with early-stage ovarian cancer who 
undergo complete surgical staging and adjuvant platinum-
based chemotherapy.29 Furthermore, rupture is often associ-
ated with dense adhesions to adjacent tissues, grade 2 or 3 
disease, and non-mucinous histology.29 These factors are 
associated with a more aggressive biological tumor behavior.
In our cohort, we recommended a platinum-based chemo-
therapy to all our patients with FIGO stage IC disease. This 
may confound the ability to detect any survival differences 
within the IC subgroups.
Limitations
Our study has some limitations. The retrospective study design 
can lead to selection bias. The incompletely staged patients 
(37.9%) might represent cases with microscopic metastasis in 
retroperitoneal lymph nodes that would be upstaged to stage 
IIIA1 instead of I. The small sample size as well as the small 
number of events represent a significant limitation to test our 
hypothesis and explain the lack of statistical power in such a 
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retrospective analysis. This represents a true concern for such 
research question, particularly when reporting data of a rare 
disease, which becomes even more demanding when split into 
subgroups. Due to our results and the results and limitations from 
the literature, we would advise that the question of staging in 
early-stage epithelial ovarian cancer should be addressed within 
a large prospective collaborative cohort, for instance within the 
rare cancer cohort of The European Network for Gynaecological 
Oncological Trial groups (ENGOT) or even Gynecologic Cancer 
INtergroup (GCIG). This, however, might not be feasible due to 
funding issues and it is questionable whether a meta-analysis of 
published data would shed any further light onto it.
Conclusion
In the present analysis, we were unable to demonstrate any 
significant prognostic differences between the subgroups of 
stage IC in the revised FIGO staging system for ovarian and 
fallopian tube carcinomas. This may be related to the small 
study size but also to the fact that 82.6% of the patients with 
stage IC disease were given adjuvant chemotherapy. The 
usefulness of the new FIGO classification in early-ovarian 
cancer remains still questionable and would need a prospec-
tive trial within a trial consortium to be properly answered.
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